Business Context and Reporting Period
Company: Biomerica, Inc. (BMRA)
Filing Type: Form 8-K (Current Report)
Date of Report: April 15, 2025
Principal Event: Implementation of a reverse stock split approved by stockholders at the December 13, 2024 Annual Meeting and authorized by the Board on April 2, 2025.
Key Financial Metrics
This filing is a corporate action report and does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The filing text does not provide a clear value for these items.
Material Changes
- Reverse Stock Split Ratio: One-for-eight (1:8).
- Effective Date: April 21, 2025, at 12:01 a.m. Eastern Time.
- Share Count Reduction: Outstanding shares will be reduced from approximately 20,366,095 to 2,545,762 (subject to rounding).
- Trading Details: Stock will begin trading on a split-adjusted basis under a new CUSIP: 09061H406.
- Fractional Shares: No fractional shares will be issued; fractional interests will be rounded up to the next whole share after aggregation.
- Authorized Shares: The number of authorized shares of common or preferred stock remains unchanged.
Guidance, Outlook, and Risks
The filing includes standard forward-looking statements regarding the reverse stock split and its potential impacts on the Company's common stock. Management disclaims any obligation to update these statements. No specific financial guidance, operational outlook, or new material risks beyond the standard disclaimer were disclosed in this document.
Investor Verification Checklist
- Confirm the new CUSIP number (09061H406) with your broker prior to the April 21, 2025 effective date.
- Verify the exact number of shares held post-split, noting the rounding up of fractional shares.
- Review the full text of the Certificate of Amendment (Exhibit 3.1) for any additional legal terms.
- Monitor trading volume and price adjustments on the Nasdaq Capital Market following the effective date.